TransMedics Group (TMDX) Misses Q1 EPS by 32c, provides guidance

TransMedics Group (NASDAQ: TMDX) reported Q1 EPS of $0.30, $0.32 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $173.9 million versus the consensus estimate of $174.47 million.

GUIDANCE:

TransMedics Group sees FY2026 revenue of $727-757 million, versus the consensus of $739 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Infleqtion raises Q2 revenue to $13.5M after contract restatement
• Bernstein SocGen Group Upgrades Whitbread PLC. (WTB:LN) (WTBCF) to Market Perform
• RBC Capital Downgrades Hermes International (RMS:FP) (HESAY) to Sector Perform